| Literature DB >> 32110181 |
Mohammad N Almohammady1, Eman M Eltahlawy2, Nashwa M Reda3.
Abstract
OBJECTIVES: Neonatal sepsis is the third leading contributor to mortality and morbidity. Emanating resistance to antibiotics in neonatal intensive care units (NICUs) is considered a major burden. In this study, we aimed to investigate the bacterial prevalence and antibiotic profile among patients admitted with sepsis in the NICU of Cairo University Children Hospital.Entities:
Keywords: Antibiotic resistance; Antibiotic sensitivity; Bacterial prevalence; Neonatal sepsis
Year: 2020 PMID: 32110181 PMCID: PMC7033391 DOI: 10.1016/j.jtumed.2019.12.005
Source DB: PubMed Journal: J Taibah Univ Med Sci ISSN: 1658-3612
Characteristics of patients with sepsis-positive blood culture.
| Characteristics | Early-onset sepsis (n = 29) | Late-onset sepsis (n = 41) | Chi square | P value |
|---|---|---|---|---|
| Gender | ||||
| Male | 17(58.6%) | 22(53.7%) | 0.17 | 0.681 |
| Female | 12(41.4%) | 19(46.3%) | ||
| Gestational age | ||||
| Preterm | 15(51.7%) | 19(46.3%) | 0.197 | 0.657 |
| Full term | 14(48.3%) | 22(53.7%) | ||
| Birth weight | ||||
| <2500 g | 15(51.7%) | 20(48.8%) | 0.059 | 0.808 |
| >2500 g | 14(48.3%) | 21(51.2%) | ||
| Mode of delivery | ||||
| Vaginal | 9(31%) | 11(26.8%) | 0.147 | 0.701 |
| Caesarean section | 20(69%) | 30(73.2%) | ||
| Premature rupture of membranes | 2(6.9%) | 1(2.4%) | 0.823 | 0.364 |
| Intervention | 11(37.9%) | 18(43.9%) | 0.25 | 0.617 |
| Mortality | 11(37.9%) | 13(31.7%) | 0.292 | 0.589 |
Data are presented as numbers (percentages).
Distribution of isolated bacteria according to sepsis onset and gestational age.
| Isolated organism (total = 75) | N (%) | Early onset | Late onset | Test proportion | P value | Preterm | Full term | Test proportion | P value |
|---|---|---|---|---|---|---|---|---|---|
| Gram-negative | |||||||||
| 34(45.3) | 17(50) | 17(50) | 0.5 | 1 | 15(44.1) | 19(55.9) | 0.5 | 0.6 | |
| 3(4) | 2(66.7) | 1(33.3) | 0.5 | 1 | 2(66.7) | 1(33.3) | 0.5 | 1 | |
| 4(5.3) | 0(0) | 4(100) | 0.5 | 0.12 | 2(50) | 2(50) | 0.5 | 1 | |
| 8(10.7) | 5(62.5) | 3(37.5) | 0.5 | o.72 | 3(37.5) | 5(62.5) | 0.5 | 0.72 | |
| Total | 49(65.3) | 24(49) | 25(51) | 0.5 | 1 | 22(44.9) | 27(55.1) | 0.5 | 0.56 |
| Gram-positive | |||||||||
| CoNS | 17(22.7) | 4(23.5) | 13(76.5) | 0.5 | 9(52.9) | 8(47.1) | 0.5 | 1 | |
| MRSA | 7(9.3) | 1(14.3) | 6(85.7) | 0.5 | 0.125 | 4(57.1) | 3(42.9) | 0.5 | 1 |
| Strept. | 2(2.7) | 2(100) | 0(0) | 0.5 | 0.12 | 0(0) | 2(100) | 0.5 | 0.12 |
| Total | 26(34.7) | 7(26.9) | 19(73.1) | 0.5 | 13(50) | 13(50) | 0.5 | 1 | |
*P < 0.05 is significant.
CoNS: coagulase-negative staphylococci; MRSA: methicillin-resistant Staphylococcus aureus; Strept.: streptococci.
Data are presented as numbers (percentages).
Types of isolates.
| Isolates | Type | Number of patients | Percentage (%) |
|---|---|---|---|
| A single isolated organism | Gram-negative | 42 | 60 |
| Gram-positive | 22 | 31.4 | |
| Two isolated organisms | Gram-negative/-positive | 4 | 5.7 |
| Gram-negative/-negative | 1 | 1.4 | |
| Gram-negative/candida | 1 | 1.4 |
Data are presented as numbers and percentages.
Differences in isolates between referred cases from another hospital and previously non-hospitalized cases.
| Isolated organism | Referred cases from another hospital | Previously non-hospitalized cases | Chi square | P value |
|---|---|---|---|---|
| Gram-negative (49) | 22 | 27 | 2.3 | |
| Gram-positive (26) | 7 | 19 | ||
| Two isolates (6) | 2 | 4 | 0.12 | 0.72 |
| Single isolate (64) | 26 | 38 |
*P < 0.05 is significant.
Data are presented as numbers.
Comparison of outcomes between single-isolate and two-isolate cases and their relation to comorbidities.
| Patients | Single isolate | Two isolates | Chi square | P value | |
|---|---|---|---|---|---|
| Mortality (n = 24) | Comorbidity | 16(25%) | 1(16.7%) | 3.6 | 0.36 |
| No comorbidity | 6 (9.4%) | 1(16.7%) | |||
| Discharged (n = 46) | Comorbidity | 13(20.3%) | 3(50%) | ||
| No comorbidity | 29(45.3%) | 1(16.7%) | |||
Data are presented as numbers (percentages).
Relative resistance of isolated organisms to relevant antibiotics.
| Antibiotics tested | Gram-negative | Gram-positive | |||||
|---|---|---|---|---|---|---|---|
| CoNS | MRSA | Strept. | |||||
| R/T (%) | R/T (%) | R/T (%) | R/T (%) | R/T (%) | R/T (%) | R/T (%) | |
| Polymyxin | 0/4(0) | 0/8(0) | |||||
| Gentamycin | 32/34(94) | 4/4(100) | 3/3(100) | 6/8(75) | 13/14(93) | 7/7(100) | 1/1(100) |
| Amikacin | 28/34(82) | 1/2 (50) | 1/3(33) | 6/8(75) | |||
| Meropenem | 32/34(94) | 1/1(100) | 3/3(100) | 1/1(100) | |||
| Imipenem | 31/34(91) | 4/4(100) | 3/3(100) | 8/8(100) | |||
| Ciprofloxacin | 28/34(82) | 4/4(100) | 1/3(33) | 6/8(75) | 13/13(100) | 7/7(100) | 2/2(100) |
| Levofloxacin | 16/34(47) | 4/4(100) | 0/3(0) | 6/8(75) | 13/14(93) | 7/7(100) | 2/2(100) |
| SXT | 29/34(85) | IR | 3/3(100) | 7/8(88) | 13/14(93) | 7/7(100) | |
| Ampicillin-sulbactam | 34/34(100) | IR | 3/3(100) | 8/8(100) | 17/17(100) | 7/7(100) | 2/2(100) |
| Amoxiclav | 34/34(100) | IR | 3/3(100) | 8/8(100) | 15/15(100) | 7/7(100) | 1/1(100) |
| Pip-tazo | 34/34(100) | 1/2(50) | 3/3(100) | 8/8(100) | |||
| Sulperazone | 34/34(100) | 1/1(100) | 3/3(100) | 8/8(100) | |||
| Ceftazidime | 34/34(100) | 3/3(100) | 8/8(100) | ||||
| Cefotaxime | 34/34(100) | IR | 3/3(100) | 8/8(100) | 14/15(93) | 7/7(100) | 0/1(0) |
| Ceftriaxone | 34/34(100) | IR | 3/3(100) | 8/8(100) | 14/14(100) | 7/7(100) | |
| Cefuroxime | 34/34(100) | IR | 3/3(100) | IR | 14/14(100) | ||
| Cefoperazone | 34/34(100) | IR | 3/3(100) | 8/8(100) | 14/14(100) | 7/7(100) | |
| Cefepime | 34/34(100) | 3/3(100) | 3/3(100) | 8/8(100) | 14/14(100) | ||
| Cefoxitin | 34/34(100) | 1/2(50) | 3/3(100) | 8/8(100) | 14/14(100) | 7/7(100) | |
| Rifampicin | 13/17(76) | 5/6(83) | |||||
| Vancomycin | 0/17(0) | 0/7(0) | 1/2(50) | ||||
| Chloramphenicol | 13/17(76) | 2/7(29) | |||||
| Linezolid | 0/6(0) | 0/3(0) | 2/2(100) | ||||
| Clindamycin | 12/17(71) | 2/7(29) | 0/1(0) | ||||
| Erythromycin | 15/17(88) | 7/7(100) | 0/1(0) | ||||
R/T: Number of resistant organisms/total; IR: intrinsic resistance; CoNS: coagulase-negative staphylococci; MRSA: methicillin-resistant Staphylococcus aureus; strept: streptococci; amociclav: amoxicillin-clavulanic acid; pip-tazo: piperacillin tazobactam; SXT: sulfamethoxazole trimethoprim.
Data are presented as numbers (percentages).